Funders › MA › Alzheimer's Disease Research Foundation › 2024
Grants paid by Alzheimer's Disease Research Foundation, tax year 2024
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2024, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 106 grants paid totaling $24,417,387. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2024
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Massachusetts General Hospital Boston, MA | A | $1,955,000 | paid | THE CUREALZ ALZHEIMER'S GENOME PROJECT | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $575,000 | paid | APOE: APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $402,500 | paid | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | APOE: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS | 202531289349302248 |
| 2024 | Northwestern University Chicago, IL | A | $345,000 | paid | MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $345,000 | paid | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts Institute of Technology Cambridge, MA | A | $300,000 | paid | DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202531289349302248 |
| 2024 | University of Rochester Rochester, NY | A | $287,500 | paid | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE. | 202531289349302248 |
| 2024 | University of California San Diego La Jolla, CA | A | $287,500 | paid | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? | 202531289349302248 |
| 2024 | New York University School of Medicine New York, NY | A | $287,500 | paid | NEUROIMMUNE CONSORTIUM: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $287,500 | paid | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION | 202531289349302248 |
| 2024 | National Institute of Neurological Disorders & Stroke Bethesda, MD | A | $287,500 | paid | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Texas Southwestern Medical Center Dallas, TX | A | $287,276 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: STRAIN REPLICATION IN MOUSE AND CELL MODELS | 202531289349302248 |
| 2024 | Northwestern University Chicago, IL | A | $286,559 | paid | ALZHEIMER'S DISEASE TAU CONSORTIUM: THE ROLE OF AB - INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | 202531289349302248 |
| 2024 | University of Pennsylvania Philadelphia, PA | A | $285,952 | paid | APOE: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY | 202531289349302248 |
| 2024 | University of California Davis Davis, CA | A | $285,851 | paid | NEUROIMMUNE CONSORTIUM: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $275,500 | paid | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $268,750 | paid | PLASMA PROTEINS, SEX AND ALZHEIMER'S DIEASE: PROTEOMEWIDE ANALYSES OF THE UK BIOBANK AND FRAMINGHAM HEART STUDY | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $258,750 | paid | DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS | 202531289349302248 |
| 2024 | The University of Chicago Chicago, IL | A | $250,000 | paid | MICROBIOME CONSORTIUM: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | 202531289349302248 |
| 2024 | The Broad Institute Inc Cambridge, MA | A | $230,000 | paid | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | SELECTIVE VULNERABILITY IN POSTERIOR CORTICAL ATROPHY | 202531289349302248 |
| 2024 | University of California Irvine Irvine, CA | A | $230,000 | paid | ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $230,000 | paid | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Memorial Sloan Kettering Cancer Center New York, NY | A | $230,000 | paid | THE ROLE OF IFITM3 AND -SECRETASE IN MICROGLIA | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $230,000 | paid | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $228,779 | paid | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? | 202531289349302248 |
| 2024 | University of Southern California Los Angeles, CA | A | $227,410 | paid | PROTECTION AGAINST ALZHEIMER'S WITH LONGEVITY-PROMOTING INTERVENTION 17A-ESTRADIOL | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $219,578 | paid | MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE | 202531289349302248 |
| 2024 | The University of Chicago Chicago, IL | A | $216,287 | paid | IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUTMICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS | 202531289349302248 |
| 2024 | Columbia University New York, NY | A | $201,279 | paid | NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION | 202531289349302248 |
| 2024 | Gladstone Institutes San Francisco, CA | A | $201,250 | paid | UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT | 202531289349302248 |
| 2024 | Stanford University Redwood City, CA | A | $201,250 | paid | MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS | 202531289349302248 |
| 2024 | The University of Texas Health Science Center at San Antonio San Antonio, TX | A | $201,250 | paid | IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | THE ROLE OF ASTROCYTE-SECRETED LGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-DEFINING A ROLE FOR THE MS4A GENES IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202531289349302248 |
| 2024 | University of Washington Seattle, WA | A | $201,250 | paid | ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDOLYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $201,250 | paid | HARVARD MEDICAL SCHOOL-DISSECTING THE MODULATORY ROLES OF IL-17RD IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Rhode Island Kingston, RI | A | $201,250 | paid | EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY - YEAR 2/2 | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-AB ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | CHARACTERIZATION OF CNS-PENETRANT HDAC 11 SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | 2024 MORBY PRIZE | 202531289349302248 |
| 2024 | The Salk Institute for Biological Studies La Jolla, CA | A | $201,250 | paid | TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Virginia Charlottesville, VA | A | $201,250 | paid | IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $201,250 | paid | IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS | 202531289349302248 |
| 2024 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | ANTIVIRAL T CELL INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN LATE ONSET ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | The Regents of the University of California San Francisco San Francisco, CA | A | $201,250 | paid | PROBING THE MOLECULAR UNDERPINNINGS OF G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATED PROTECTIVE MICROGLIAL RESPONSES TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | New York University School of Medicine New York, NY | A | $201,250 | paid | MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE ONSET ALZHEIMER'S DISEASE IN WOMEN | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $201,250 | paid | ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS | 202531289349302248 |
| 2024 | Carnegie Mellon University Pittsburgh, PA | A | $201,250 | paid | INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202531289349302248 |
| 2024 | Mayo Clinic Jacksonville Jacksonville, FL | A | $201,250 | paid | RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of California San Diego La Jolla, CA | A | $201,250 | paid | DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | University of Virginia Charlottesville, VA | A | $201,250 | paid | ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE | 202531289349302248 |
| 2024 | Univeristy of California Los Angeles Los Angeles, CA | A | $201,250 | paid | NOVEL AI DECODES AGING NEURONS | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS | 202531289349302248 |
| 2024 | University of California Irvine Irvine, CA | A | $201,250 | paid | BIOINFORMATICS PLATFORM FOR MODELING ALZHEIMER'S PROGRESSION (MAP-AD PLATFORM) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $201,250 | paid | TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,250 | paid | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $201,250 | paid | ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Wake Forest University Health Sciences Winstonsalem, NC | A | $201,250 | paid | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE | 202531289349302248 |
| 2024 | Dana-Farber Cancer Institute Inc Boston, MA | A | $201,250 | paid | PRE-CLINICAL TESTING OF CDK4/6 INHIBITORS AS A THERAPEUTIC STRATEGY IN ALZHEIMER'S DISEASE USING AD TAUOPATHY MOUSE MODEL | 202531289349302248 |
| 2024 | Beth Israel Deadoness Medical Center Boston, MA | A | $201,235 | paid | INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $201,234 | paid | T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $201,227 | paid | CIRCUIT DYNAMICS IN APOE4 MICE | 202531289349302248 |
| 2024 | Indiana University Bloomington, IN | A | $200,631 | paid | MODULATING THE LEVELS OF TAU-SEED INTERACTORS TO TREAT ALZHEIMER'S DISEASES | 202531289349302248 |
| 2024 | Weill Medical College of Cornell University New York, NY | A | $200,532 | paid | HYPERTENSION, TAU AND NEURODEGENERATION | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $200,356 | paid | MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS | 202531289349302248 |
| 2024 | Yale University New Haven, CT | A | $199,995 | paid | THE ROLE OF CALCIUM HOMEOSTASIS IN AXONAL SPHEROID FORMATION IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Brigham and Women's Hospital Boston, MA | A | $195,250 | paid | TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $192,314 | paid | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | 202531289349302248 |
| 2024 | President and Fellows of Harvard College Cambridge, MA | A | $187,315 | paid | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA | 202531289349302248 |
| 2024 | Indiana University Bloomington, IN | A | $180,419 | paid | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | 202531289349302248 |
| 2024 | Burke Neurological Institute White Plains, NY | A | $173,007 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 | 202531289349302248 |
| 2024 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,786 | paid | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | 202531289349302248 |
| 2024 | University of Michigan Ann Arbor, MI | A | $148,773 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | 202531289349302248 |
| 2024 | Baylor College of Medicine Houston, TX | A | $138,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Massachusetts General Hospital Boston, MA | A | $125,000 | paid | THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $123,098 | paid | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | 202531289349302248 |
| 2024 | St Jude Children's Research Hospital Memphis, TN | A | $92,000 | paid | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Boston Children's Hospital Boston, MA | A | $86,250 | paid | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE - SUPPLEMENT TO YR 1 (OF2) | 202531289349302248 |
| 2024 | Washington University in St Louis St Louis, MO | A | $52,477 | paid | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | 202531289349302248 |
| 2024 | Duke University School of Medicine Durham, NC | A | $24,957 | paid | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | 202531289349302248 |
| 2024 | University of Miami Atlanta, GA | A | $24,589 | paid | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | 202531289349302248 |
| 2024 | Medical College of Wisconsin Milwaukee, WI | A | $4,721 | paid | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | 202531289349302248 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.